
-
Inhibrx Inc. NasdaqGS:INBX Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates include INBRX-109, a tetravalent therapeutic candidate targeting death-receptor 5 to treat unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head and neck squamous cell carcinoma, gastric or gastroesophageal junction adenocarcinoma, renal cell carcinoma, and urothelial cell carcinoma. Inhibrx Biosciences, Inc. was incorporated in 2024 and is based in La Jolla, California.
Location: 11025 North Torrey Pines Road, La Jolla, La Jolla, CA, 92037, United States | Website: https://inhibrx.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
89.05M
Cash
216.5M
Avg Qtr Burn
-41.81M
Short % of Float
9.81%
Insider Ownership
27.19%
Institutional Own.
68.12%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Ozekibart (INBRX-109) (DR5 agonist) Details Solid tumor/s, Cancer, Chondrosarcoma Suspected Mover™ Susp. Mover™ | Phase 2 Data readout | |
Ozekibart (INBRX-109) (DR5 agonist) Details Relapsed/refractory Ewing sarcoma | Phase 1 Data readout | |
INBRX-106 (OX40 agonist) +/- Keytruda Details Solid tumor/s, Cancer | Phase 1 Data readout | |
Ozekibart (INBRX-109) + FOLFIRI Details Cancer, Colorectal cancer , Metastatic colorectal cancer | Phase 1 Data readout | |
INBRX-105 (PDL1 X 4-1BB tetravalent conditional agonist) +/- Keytruda Details Cancer, Solid tumor/s | Failed Discontinued |